News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
The Danish biotech company confirmed the global study will begin in the second half of 2026
Health innovations are viewed more positively than food and agricultural technologies
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Company to highlight science-backed actives, nature-powered ingredients, and its new “Natural by Barentz” private label platform in Barcelona
New medical and wellness centre combines on-site care with telehealth to support industrial workforce and surrounding communities
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
